MedTrace Logo

Safety and Efficacy Study of a Dual PI3K Delta/Gamma Inhibitor in T-cell Lymphoma

NCT02567656 · Status: COMPLETED · Phase: PHASE1 · Type: INTERVENTIONAL · Enrollment: 58

Last updated 2020-01-13

Study results available
· View outcomes & findings →

Summary

The purpose of this study is to evaluate the safety, PK and efficacy of RP6530, a dual PI3K delta/gamma inhibitor in patients with relapsed and refractory T-cell Lymphoma.

Conditions

  • Lymphoma, T-Cell, Peripheral
  • Lymphoma, T-Cell, Cutaneous

Interventions

DRUG

RP6530

Tablet starting at 200 mg

Sponsors & Collaborators

  • Rhizen Pharmaceuticals SA

    lead INDUSTRY

Principal Investigators

  • Auris Huen, MD · MD Anderson Cancer Center, Houston, Tx.

Study Design

Allocation
NA
Purpose
TREATMENT
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2015-09-30
Primary Completion
2018-03-31
Completion
2018-12-10

Countries

  • United States

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT02567656 on ClinicalTrials.gov